Correlation Between Veracyte and Standard Biotools

Can any of the company-specific risk be diversified away by investing in both Veracyte and Standard Biotools at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Veracyte and Standard Biotools into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Veracyte and Standard Biotools, you can compare the effects of market volatilities on Veracyte and Standard Biotools and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Veracyte with a short position of Standard Biotools. Check out your portfolio center. Please also check ongoing floating volatility patterns of Veracyte and Standard Biotools.

Diversification Opportunities for Veracyte and Standard Biotools

-0.15

Correlation Coefficient

Veracyte  Standard Biotools

Good diversification

The 3 months correlation between Veracyte and Standard is -0.15. Overlapping area represents the amount of risk that can be diversified away by holding Veracyte and Standard Biotools in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Standard Biotools and Veracyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Veracyte are associated (or correlated) with Standard Biotools. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Standard Biotools has no effect on the direction of Veracyte i.e., Veracyte and Standard Biotools go up and down completely randomly.

Pair Corralation between Veracyte and Standard Biotools

Given the investment horizon of 90 days Veracyte is expected to under-perform the Standard Biotools. But the stock apears to be less risky and, when comparing its historical volatility, Veracyte is 2.17 times less risky than Standard Biotools. The stock trades about -0.12 of its potential returns per unit of risk. The Standard Biotools is currently generating about 0.1 of returns per unit of risk over similar time horizon. If you would invest  111.00  in Standard Biotools on May 1, 2025 and sell it today you would earn a total of  28.00  from holding Standard Biotools or generate 25.23% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	98.39%
Values	Daily Returns

Veracyte  vs.  Standard Biotools

Veracyte

Risk-Adjusted Performance

Very Weak

Over the last 90 days Veracyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in August 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Standard Biotools

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Standard Biotools are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Standard Biotools sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Veracyte and Standard Biotools

The main advantage of trading using opposite Veracyte and Standard Biotools positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Veracyte position performs unexpectedly, Standard Biotools can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Standard Biotools will offset losses from the drop in Standard Biotools' long position.

The idea behind Veracyte and Standard Biotools pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..